| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATORY BOWEL DISEASE |
1 Mayo Clinic, Rochester, MN, USA
2 University of Chicago, Chicago, IL, USA
3 Universitaire Ziekenhuizen Leuven, UZ Gasthuisberg, Leuven, Belgium
4 University of Alberta, Edmonton, Alberta, Canada
5 Charles University, Prague, Czech Republic
6 Dalhousie University, Halifax, Nova Scotia, Canada
7 University of Calgary, Calgary, Alberta, Canada
8 Atlanta Gastroenterology Associates, Atlanta, GA, USA
9 Abbott Laboratories, Abbott Park, Illinois, USA
10 Abbott Laboratories, Parsippany, New Jersey, USA
Correspondence to:
Correspondence to:
Dr William J Sandborn
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.william{at}mayo.edu
Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn’s disease in the CLASSIC I trial.
Objective: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn’s disease in a follow-on randomised controlled trial (CLASSIC II).
Methods: In the preceding CLASSIC I trial, 299 patients with moderate to severe Crohn’s disease naive to tumour necrosis factor antagonists received induction therapy with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg, or placebo, at weeks 0 and 2. In all, 276 patients from CLASSIC I enrolled in CLASSIC II and received open-label adalimumab 40 mg at weeks 0 (week 4 of CLASSIC I) and 2; 55 patients in remission at both weeks 0 and 4 were re-randomised to adalimumab 40 mg every other week, 40 mg weekly, or placebo for 56 weeks. Patients not in remission at both weeks 0 and 4 were enrolled in an open-label arm and received adalimumab 40 mg every other week. With non-response or flare, these patients could have their dosages increased to 40 mg weekly. Patients in the randomised arm with continued non-response or disease flare could switch to open-label adalimumab 40 mg every other week and again to 40 mg weekly. The primary end point was maintenance of remission (CDAI <150) in randomised patients through week 56.
Results: Of 55 patients randomised at week 4, 79% who received adalimumab 40 mg every other week and 83% who received 40 mg weekly were in remission at week 56, v 44% for placebo (p<0.05). In all, 204 patients entered the open-label arm. Of these, 93 (46%) were in clinical remission at week 56. Adalimumab was generally well-tolerated in all patients.
Conclusions: Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn’s disease naive to anti-TNF treatment.
Abbreviations: ANA, antinuclear antibodies; CDAI, clinical disease activity index; CLASSIC: Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction Therapy in Crohn’s Disease trial; IBDQ, inflammatory bowel disease questionnaire; LOCF, last observation carried forward
Keywords: gastroenterology; Crohn’s disease; adalimumab; tumour necrosis factor antagonists; randomised controlled trial
Related Article
Gut 2007 56: 1184-1186.
This article has been cited by other articles:
|
|
 |
|
  J.-F. Colombel, A. J M Watson, and M. F Neurath The 10 remaining mysteries of inflammatory bowel disease Gut, April 1, 2008; 57(4): 429 - 433. [Full Text] [PDF]
|
|
|
|
|
|
J. Panes and S. Ghosh The classics in perspective Gut, September 1, 2007; 56(9): 1184 - 1186. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mannon GAIN for Loss: Adalimumab for Infliximab-Refractory Crohn Disease Ann Intern Med, June 19, 2007; 146(12): 888 - 890. [Full Text] [PDF]
|
|
|
|
|
|
W. J. Sandborn, P. Rutgeerts, R. Enns, S. B. Hanauer, J.-F. Colombel, R. Panaccione, G. D'Haens, J. Li, M. R. Rosenfeld, J. D. Kent, et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial Ann Intern Med, June 19, 2007; 146(12): 829 - 838. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
